Two studies will help determine whether health care workers in Canada are at higher risk of contracting SARS-CoV-2
Preliminary, non-peer reviewed results suggest that in phase 1 of a study on healthcare workers led by Dr. Nicola Cherry at the University of Alberta, rates of infection were higher in physicians than in other HCWs and higher in Quebec physicians than among physicians in Alberta.
Decline of Humoral Responses against SARS-CoV-2 Spike in Convalescent Individuals
A group of Canadian researchers, led by Andrés Finzi from the Université de Montréal, investigated the duration of antibodies against SARS-CoV-2 in people who were recovering from COVID-19.
Researchers find antibodies capable of blocking infection in recovered COVID-19 patients, but they may not last long
Researchers from Université de Montréal and Héma Québec, led by Dr. Andrés Finzi and Dr. Renée Bazin, and working with collaborators across Canada, are reporting that antibodies against SARS-CoV-2 Spike correlate with COVID-19 severity.
Final results of initial Canadian SARS-CoV-2 seroprevalence study announced
Study suggests as few as 0.7% of adults have antibodies to SARS-CoV-2 Canadian Blood Services and Canada’s COVID-19 Immunity Task Force (CITF) are releasing final results of a collaborative nine-province SARS-CoV-2 seroprevalence study. This analysis, based on 37,373 blood samples from blood donor centres across Canada (except Quebec and the Territories), reveals that fewer than 1 per cent of Canadian blood donors tested positive for antibodies [...]
SeroTracker: a global SARS-CoV-2 seroprevalence dashboard
An interdisciplinary group of health researchers, engineers, and economists has come together to gather and centralize seroprevalence data on one site, SeroTracker.
New study offers first glimpse into how widespread COVID-19 antibodies are in Canada’s adult population
Canadian Blood Services and the CITF reveal that over the period May 9 through June 8, 2020, fewer than 1 per cent of the 10,000 samples from blood donors tested positive for antibodies to the novel coronavirus.